Retrospective cohort study compares outcomes of molar and non-molar gestational trophoblastic neoplasia, indicating survival driven by disease severity.
Background: Gestational trophoblastic neoplasia (GTN) is rare but highly curable. This study compared clinical characteristics and outcomes between molar and non-molar disease. Methods: This retrospective cohort included 550 patients at a Brazilian reference center (1985–2025). Survival was assessed using Kaplan–Meier methods. Multivariable analyses included Poisson and Cox regression models. Results: Molar GTN comprised 86% of cases. Non-molar GTN (14%) presented with more advanced FIGO stages, higher WHO risk scores, and more metastases (p < 0.001). Overall five-year disease-specific survival (DSS) was 97.4% (95% CI 95.9–98.9) and progression-free survival (PFS) was 92.4% (95% CI 90.1–94.7). Non-molar disease had lower DSS (84.4% vs. 99.8%; p < 0.001) and PFS (85.3% vs. 93.5%; p = 0.049) in unadjusted analyses. However, after multivariable adjustment, GTN type was not independently associated with DSS (HR 9.41; 95% CI 0.70–127; p = 0.092) or PFS (HR 1.61; 95% CI 0.57–4.60; p = 0.372). Non-molar patients had a lower likelihood of subsequent pregnancy (RR 0.60; 95% CI 0.36–1.00; p = 0.049). Conclusions: Although non-molar GTN presents with more aggressive clinical features, survival outcomes appear to be primarily driven by baseline disease severity rather than GTN subtype itself.
No takes yet. Share an insight, caveat, or question.
Uberti et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: